MedPath

MAIA Biotechnology's Shares Surge Following FDA Approval of Telomerase Inhibitor

• MAIA Biotechnology's stock increased by 14% following the FDA's approval of imetelstat, validating telomere targeting as a viable therapeutic approach. • The FDA approved Geron Corp's imetelstat for treating rare blood cancers originating in bone marrow, specifically low- to intermediate-risk myelodysplastic syndromes. • MAIA Biotechnology is currently studying THIO, a telomere targeting agent, in a Phase 2 trial for high-risk non-small cell lung cancer (NSCLC). • MAIA's CEO, Vlad Vitoc, emphasized the crucial role of telomere targeting in treating certain cancers, highlighting THIO's mechanism of action.

MAIA Biotechnology's shares experienced a significant rise after the FDA's approval of Geron Corp's imetelstat, a telomerase inhibitor, which Maia believes validates the viability of telomere targeting functionality, used by its THIO candidate. The stock price jumped 14% to $3.79 following the announcement. This development underscores the potential of therapies leveraging the cell's telomeric functions.
The FDA approved imetelstat for the treatment of low- to intermediate-risk hematologic malignancies, specifically myelodysplastic syndromes (MDS), rare blood cancers originating in the bone marrow. This regulatory milestone is seen as a validation of telomere targeting as a mechanism of action in cancer therapy.

THIO's Role in NSCLC Treatment

MAIA Biotechnology's lead candidate, THIO, is a telomere targeting agent currently in Phase 2 clinical development. The trial is evaluating THIO's activity in high-risk non-small cell lung cancer (NSCLC). THIO is designed to be recognized by telomerase and incorporated into telomeres within cancer cells, disrupting their function.
According to MAIA Chief Executive Vlad Vitoc, telomere targeting plays a key role in treating certain cancers. The ongoing Phase 2 trial aims to further explore the efficacy and safety of THIO in patients with high-risk NSCLC.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

MAIA Biotechnology and BeiGene Collaborate to Evaluate THIO in Multiple Cancers

MAIA Biotechnology and BeiGene enter a clinical supply agreement to assess THIO, combined with tislelizumab, in Phase 2 trials.
The trials will focus on hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), and colorectal cancer (CRC).

FDA Approves Checkpoint Therapeutics' Unloxcyt (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma

The FDA has granted approval to Checkpoint Therapeutics' Unloxcyt (cosibelimab-ipdl) for the treatment of advanced cutaneous squamous cell carcinoma (cSCC).
Unloxcyt, a PD-L1 antibody, represents Checkpoint Therapeutics' first FDA-approved drug, marking a significant milestone for the company.

MAIA Biotechnology Expands THIO-101 Trial Following Positive Interim Results; Directors Increase Stock Holdings

MAIA Biotechnology's Phase 2 THIO-101 trial, evaluating THIO with Regeneron's Libtayo® for third-line NSCLC, is expanding due to promising interim results.
Interim data from the THIO-101 trial showed a median survival follow-up of 10.6 months, compared favorably to the 5.8-month standard-of-care overall survival.

Biofrontera's Ameluz Demonstrates High Efficacy in Phase III sBCC Trial

Biofrontera's Ameluz-PDT therapy met the primary endpoint, showing 65.5% success in complete clearance of superficial basal cell carcinoma (sBCC) lesions, compared to 4.8% with placebo.
The Phase III trial demonstrated that 75.9% of participants treated with Ameluz-PDT achieved complete histological clearance, versus 19% in the placebo group.

Viridian Therapeutics' Veligrotug Achieves Positive Phase III Results in Thyroid Eye Disease

Viridian Therapeutics' veligrotug met all primary and secondary endpoints in the Phase III THRIVE trial for active thyroid eye disease (TED).
The trial demonstrated statistically significant improvements in signs and symptoms of TED after 15 weeks of veligrotug treatment compared to placebo.

MAIA Biotechnology's THIO Shows Promising Results in NSCLC Trial

MAIA Biotechnology's THIO, a telomere-targeting agent, demonstrates encouraging clinical activity in advanced non-small cell lung cancer (NSCLC).
In the Phase 2 THIO-101 trial, THIO combined with cemiplimab showed a 38% overall response rate in third-line NSCLC patients.

MAIA Biotechnology Completes Enrollment in Phase 2 THIO-101 Trial for Advanced NSCLC

MAIA Biotechnology completed enrollment in its Phase 2 THIO-101 trial, evaluating THIO sequenced with cemiplimab for advanced NSCLC.
The trial reached its target of 41 patients at the 180mg dose, selected as optimal in December 2023, ahead of the initial schedule.

FDA Grants Fast Track Designation to Immuneering's IMM-1-104 for Pancreatic Cancer

The FDA has granted Fast Track designation to Immuneering's IMM-1-104 for pancreatic ductal adenocarcinoma after one prior line of therapy.
This designation aims to expedite the development and review of IMM-1-104, addressing a critical unmet need in pancreatic cancer treatment.

MAIA Biotechnology's THIO Shows Promise in Phase 2 NSCLC Trial

MAIA Biotechnology's THIO, combined with Libtayo®, demonstrates a 100% disease control rate in second-line NSCLC patients in the THIO-101 Phase 2 trial.
The THIO-101 trial is evaluating THIO's anti-tumor activity and its potential to enhance immune response when followed by PD-(L)1 inhibition in advanced NSCLC.

FDA Approves Krystal Biotech's Vyjuvek, a Topical Gene Therapy for Dystrophic Epidermolysis Bullosa

The FDA has approved Vyjuvek, Krystal Biotech's topical gene therapy, marking the first treatment of its kind for dystrophic epidermolysis bullosa.
Vyjuvek is approved for patients aged six months and older with either recessive or dominant forms of dystrophic epidermolysis bullosa.

Reference News

[1]
MAIA Biotechnology Shares Rise After FDA's Telomerase Inhibitor ...
morningstar.com · Jun 7, 2024

MAIA Biotechnology shares surged 14% to $3.79 after FDA's approval of imetelstat validated telomere targeting therapies....

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy